178 related articles for article (PubMed ID: 36246971)
1. SOX8 Knockdown Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer by Inhibiting the Notch Signaling Pathway.
Du Z; Chen X; Zhu P; Sun W; Lv Q; Cheng S; Yang X; Yu X
Biomed Res Int; 2022; 2022():9235837. PubMed ID: 36246971
[TBL] [Abstract][Full Text] [Related]
2. Knocking down SOX2 overcomes the resistance of prostate cancer to castration via notch signaling.
Du Z; Chen X; Zhu P; Lv Q; Yong J; Gu J
Mol Biol Rep; 2023 Nov; 50(11):9007-9017. PubMed ID: 37716921
[TBL] [Abstract][Full Text] [Related]
3. CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.
Chen X; Wu Y; Wang X; Xu C; Wang L; Jian J; Wu D; Wu G
Eur J Med Res; 2022 Jul; 27(1):105. PubMed ID: 35780240
[TBL] [Abstract][Full Text] [Related]
4. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
5. HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro.
Du Z; Li L; Sun W; Wang X; Zhang Y; Chen Z; Yuan M; Quan Z; Liu N; Hao Y; Li T; Wang J; Luo C; Wu X
Int J Oncol; 2018 Jul; 53(1):99-112. PubMed ID: 29658567
[TBL] [Abstract][Full Text] [Related]
6. MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC.
Wang Y; Chen J; Gong L; Wang Y; Siltari A; Lou YR; Murtola TJ; Gao S; Gao Y
J Nanobiotechnology; 2024 Apr; 22(1):145. PubMed ID: 38566211
[TBL] [Abstract][Full Text] [Related]
7. Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/ androgen receptor signaling pathway.
Chen X; Yang G; Liu M; Quan Z; Wang L; Luo C; Wu X; Zheng Y
Biochem Biophys Res Commun; 2022 Jul; 613():53-60. PubMed ID: 35533600
[TBL] [Abstract][Full Text] [Related]
8. Construction of enzalutamide-resistant cell model of prostate cancer and preliminary screening of potential drug-resistant genes.
Feng T; Wei D; Zhao J; Li Q; Guo P; Yang X; Li M; Jiang Y; Luo Y
Exp Biol Med (Maywood); 2021 Aug; 246(15):1776-1787. PubMed ID: 34034559
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoid Receptor (GR) Activation Is Associated with Increased cAMP/PKA Signaling in Castration-Resistant Prostate Cancer.
Bennett L; Jaiswal PK; Harkless RV; Long TM; Gao N; Vandenburg B; Selman P; Durdana I; Lastra RR; Vander Griend D; Adelaiye-Ogala R; Szmulewitz RZ; Conzen SD
Mol Cancer Ther; 2024 Apr; 23(4):552-563. PubMed ID: 38030378
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC).
Kong Y; Cheng L; Mao F; Zhang Z; Zhang Y; Farah E; Bosler J; Bai Y; Ahmad N; Kuang S; Li L; Liu X
J Biol Chem; 2018 Sep; 293(37):14328-14341. PubMed ID: 30089652
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
12. Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.
Liu JS; Fang WK; Yang SM; Wu MC; Chen TJ; Chen CM; Lin TY; Liu KL; Wu CM; Chen YC; Chuu CP; Wang LY; Hsieh HP; Kung HJ; Wang WC
J Biomed Sci; 2022 May; 29(1):29. PubMed ID: 35534851
[TBL] [Abstract][Full Text] [Related]
13.
Luk IS; Shrestha R; Xue H; Wang Y; Zhang F; Lin D; Haegert A; Wu R; Dong X; Collins CC; Zoubeidi A; Gleave ME; Gout PW; Wang Y
Clin Cancer Res; 2017 Mar; 23(6):1542-1551. PubMed ID: 27663589
[No Abstract] [Full Text] [Related]
14. Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide.
Li J; Hong Z; Zhang J; Zheng S; Wan F; Liu Z; Dai B
Oncogene; 2024 Mar; 43(10):744-757. PubMed ID: 38243079
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
[TBL] [Abstract][Full Text] [Related]
16. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
[TBL] [Abstract][Full Text] [Related]
17. Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment.
Ning S; Liu C; Lou W; Yang JC; Lombard AP; D'Abronzo LS; Batra N; Yu AM; Leslie AR; Sharifi M; Evans CP; Gao AC
Mol Cancer Ther; 2022 Oct; 21(10):1594-1607. PubMed ID: 35930737
[TBL] [Abstract][Full Text] [Related]
18. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
Yamamoto Y; Loriot Y; Beraldi E; Zhang F; Wyatt AW; Al Nakouzi N; Mo F; Zhou T; Kim Y; Monia BP; MacLeod AR; Fazli L; Wang Y; Collins CC; Zoubeidi A; Gleave M
Clin Cancer Res; 2015 Apr; 21(7):1675-87. PubMed ID: 25634993
[TBL] [Abstract][Full Text] [Related]
19. Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer.
Zhao J; Zhao Y; Wang L; Zhang J; Karnes RJ; Kohli M; Wang G; Huang H
Oncotarget; 2016 Jun; 7(25):38551-38565. PubMed ID: 27221037
[TBL] [Abstract][Full Text] [Related]
20. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
